APONTIS PHARMA AG (APPH.DE) Stock Fundamental Analysis
FRA:APPH - Deutsche Boerse Ag - DE000A3CMGM5 - Common Stock - Currency: EUR
We assign a fundamental rating of 4 out of 10 to APPH. APPH was compared to 53 industry peers in the Pharmaceuticals industry. APPH has a great financial health rating, but its profitability evaluates not so good. APPH is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year APPH was profitable.
APPH had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: APPH reported negative net income in multiple years.
In multiple years APPH reported negative operating cash flow during the last 5 years.
1.2 Ratios
APPH's Return On Assets of 2.82% is on the low side compared to the rest of the industry. APPH is outperformed by 60.38% of its industry peers.
Looking at the Return On Equity, with a value of 4.03%, APPH is doing worse than 60.38% of the companies in the same industry.
APPH has a worse Return On Invested Capital (2.95%) than 62.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.82% | ||
| ROE | 4.03% | ||
| ROIC | 2.95% |
ROA(3y)-4.49%
ROA(5y)-3.77%
ROE(3y)-9.48%
ROE(5y)-12.88%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 1.75%, APPH is doing worse than 62.26% of the companies in the same industry.
The Operating Margin of APPH (2.47%) is worse than 66.04% of its industry peers.
In the last couple of years the Operating Margin of APPH has declined.
APPH has a Gross Margin of 57.57%. This is in the lower half of the industry: APPH underperforms 69.81% of its industry peers.
In the last couple of years the Gross Margin of APPH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.47% | ||
| PM (TTM) | 1.75% | ||
| GM | 57.57% |
OM growth 3Y-32.75%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.69%
GM growth 5Y-4.61%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so APPH is destroying value.
APPH has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for APPH has been reduced compared to 5 years ago.
APPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
APPH has an Altman-Z score of 6.41. This indicates that APPH is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of APPH (6.41) is better than 88.68% of its industry peers.
APPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.41 |
ROIC/WACC0.42
WACC7.03%
2.3 Liquidity
APPH has a Current Ratio of 4.44. This indicates that APPH is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of APPH (4.44) is better than 100.00% of its industry peers.
APPH has a Quick Ratio of 3.37. This indicates that APPH is financially healthy and has no problem in meeting its short term obligations.
APPH's Quick ratio of 3.37 is amongst the best of the industry. APPH outperforms 94.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.44 | ||
| Quick Ratio | 3.37 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 106.67% over the past year.
APPH shows a strong growth in Revenue. In the last year, the Revenue has grown by 31.12%.
Measured over the past years, APPH shows a small growth in Revenue. The Revenue has been growing by 3.89% on average per year.
EPS 1Y (TTM)106.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.67%
Revenue 1Y (TTM)31.12%
Revenue growth 3Y-1.8%
Revenue growth 5Y3.89%
Sales Q2Q%43.76%
3.2 Future
The Earnings Per Share is expected to grow by 128.83% on average over the next years. This is a very strong growth
APPH is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.31% yearly.
EPS Next Y290.99%
EPS Next 2Y175.34%
EPS Next 3Y128.83%
EPS Next 5YN/A
Revenue Next Year15.94%
Revenue Next 2Y18.51%
Revenue Next 3Y19.03%
Revenue Next 5Y15.31%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 79.67, which means the current valuation is very expensive for APPH.
APPH's Price/Earnings ratio is a bit more expensive when compared to the industry. APPH is more expensive than 67.92% of the companies in the same industry.
When comparing the Price/Earnings ratio of APPH to the average of the S&P500 Index (26.43), we can say APPH is valued expensively.
The Price/Forward Earnings ratio is 26.99, which means the current valuation is very expensive for APPH.
Compared to the rest of the industry, the Price/Forward Earnings ratio of APPH indicates a slightly more expensive valuation: APPH is more expensive than 67.92% of the companies listed in the same industry.
APPH's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 22.17.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 79.67 | ||
| Fwd PE | 26.99 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, APPH is valued a bit more expensive than 66.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 21.49 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
APPH's earnings are expected to grow with 128.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.27
PEG (5Y)N/A
EPS Next 2Y175.34%
EPS Next 3Y128.83%
5. Dividend
5.1 Amount
No dividends for APPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:APPH (6/4/2025, 7:00:00 PM)
11.95
+0.35 (+3.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners45.55%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap101.58M
Analysts43.33
Price Target13.77 (15.23%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.89%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)5.98%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.51%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 79.67 | ||
| Fwd PE | 26.99 | ||
| P/S | 1.42 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.27 | ||
| P/tB | 7.6 | ||
| EV/EBITDA | 21.49 |
EPS(TTM)0.15
EY1.26%
EPS(NY)0.44
Fwd EY3.7%
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS8.43
BVpS3.65
TBVpS1.57
PEG (NY)0.27
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.82% | ||
| ROE | 4.03% | ||
| ROCE | 4.51% | ||
| ROIC | 2.95% | ||
| ROICexc | 4.86% | ||
| ROICexgc | 18.85% | ||
| OM | 2.47% | ||
| PM (TTM) | 1.75% | ||
| GM | 57.57% | ||
| FCFM | N/A |
ROA(3y)-4.49%
ROA(5y)-3.77%
ROE(3y)-9.48%
ROE(5y)-12.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-34.78%
ROICexcg growth 5YN/A
ROICexc growth 3Y-37.05%
ROICexc growth 5YN/A
OM growth 3Y-32.75%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.69%
GM growth 5Y-4.61%
F-Score5
Asset Turnover1.61
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 104.52% | ||
| Cap/Sales | 3.27% | ||
| Interest Coverage | 13.13 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.44 | ||
| Quick Ratio | 3.37 | ||
| Altman-Z | 6.41 |
F-Score5
WACC7.03%
ROIC/WACC0.42
Cap/Depr(3y)153.41%
Cap/Depr(5y)119.86%
Cap/Sales(3y)6.51%
Cap/Sales(5y)4.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)106.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.67%
EPS Next Y290.99%
EPS Next 2Y175.34%
EPS Next 3Y128.83%
EPS Next 5YN/A
Revenue 1Y (TTM)31.12%
Revenue growth 3Y-1.8%
Revenue growth 5Y3.89%
Sales Q2Q%43.76%
Revenue Next Year15.94%
Revenue Next 2Y18.51%
Revenue Next 3Y19.03%
Revenue Next 5Y15.31%
EBIT growth 1Y113.23%
EBIT growth 3Y-33.96%
EBIT growth 5YN/A
EBIT Next Year419.89%
EBIT Next 3Y131.3%
EBIT Next 5YN/A
FCF growth 1Y66.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y76.97%
OCF growth 3YN/A
OCF growth 5YN/A